Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 2/20 | 0.35 |
| ▸ | SELP | P16109 | 5/20 | 0.34 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | VEGFA | P15692 | 5/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | FGF1 | P05230 | 3/20 | 0.31 |
| ▸ | FGF2 | P09038 | 3/20 | 0.31 |
| ▸ | HPSE | Q9Y251 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17167763 | 0.91 | SELP (0.33) | TLR4SELPAKT1VEGFA | |
| SCHEMBL17167853 | 0.87 | F10 (0.43) | SELPVEGFAHPSE | |
| SCHEMBL18914844 | 0.87 | — | — | |
| SCHEMBL17167545 | 0.87 | F10 (0.43) | SELPVEGFAHPSE | |
| SCHEMBL17167726 | 0.80 | HPSE (0.31) | FGF1FGF2HPSE | |
| SCHEMBL17167546 | 0.80 | F10 (0.45) | SELPVEGFAFGF1FGF2HPSE | |
| SCHEMBL18914846 | 0.80 | — | — | |
| SCHEMBL17167667 | 0.76 | HPSE (0.47) | VEGFAMAPK1FGF1FGF2HPSE | |
| SCHEMBL8150299 | 0.69 | IGF2R (0.53) | TLR4SELPVEGFAMAPK1FGF1 | |
| SCHEMBL17167553 | 0.69 | BDNF (0.55) | SELPVEGFAFGF1FGF2HPSE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170152279-A9 | Saccharide Dendritic Cluster Compounds as Inhibitors of Bace-1 | UNIVERSITY OF LIVERPOOL (GB) | 2017-06-01 | — | — | US | disclosed |
| US-20150291644-A1 | Saccharide Dendritic Cluster Compounds as Inhibitors of Bace-1 | VICTORIA LINK LTD (NZ) | 2015-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291644-A1 | Saccharide Dendritic Cluster Compounds as Inhibitors of Bace-1 | BACE1, BACE2, APP | TLR4 2252/4885SELP 363/4885AKT1 2465/4885 |
| US-20170152279-A9 | Saccharide Dendritic Cluster Compounds as Inhibitors of Bace-1 | BACE1, BACE2, APP | TLR4 2252/4885SELP 363/4885AKT1 2465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.